Wound Healing Following Penile Prosthesis Implant

Erectile Dysfunction Clinical Trial

Official title:

Randomized Control Trial of Vivex Tissue for Accelerated Wound Healing Following Penile Prosthesis Placement With Follow-up

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05196191
• Other study ID #: CYG-2021-001
• Status: Terminated
• Phase: N/A
• Start date: January 3, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: February 2024
• Source: VIVEX Biologics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on men undergoing penile implant surgery for the first time. The patients are randomized in a 2:1 ratio of active to sham treatment groups.

Description:

Erectile Dysfunction (ED) is a condition with an inability to develop or maintain an erection of the penis upon sexual stimulation. It occurs in association with aging, chronic illnesses and various modifiable risk factors. Amongst the modifiable risk factors, ED shares the most common risk factors with Coronary Artery Disease (CAD) which are smoking, hypertension and hyperlipidemia. Even though it is not a part of normal aging, it is seen in 52% of men in the age group 40 to 70 years, with a higher rate in the men more than 70 years.

VIAGENEX Max is a semi-transparent, collagenous membrane intended for soft tissue barrier or wound covering, derived from umbilical cord membrane. A total of 50 subjects with ED meeting the eligibility criteria will be randomized. The treatment graft will be placed into the wound at time of surgery. The treatment group will receive the VIAGENEX graft and the sham group will receive the standard of care for this surgery.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 32
• Est. completion date: December 30, 2023
• Est. primary completion date: December 13, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 30 Years to 70 Years

Eligibility

Inclusion Criteria:

• The patient must be willing and able to provide informed consent

• The patient is a male between >/= 30 and =/< 70 years of age

• The patient has ED based of International Index of Erectile Dysfunction (IIEF) scores

• The patient has been in a stable relationship for over 3 months prior to enrollment

• A minimum of 2 sexual attempts per month for at least one month prior to enrollment - as documented by IIEF

• The patient is suffering from erectile dysfunction and undergoing penile implant surgery for the first time

• IIEF-EF score between 16 and 25

• Testosterone level 300-1000 ng/dL within 1 month prior to enrollment

• A1C level </= 7% within 1 month prior to enrollment

Exclusion Criteria:

• The patient is currently or has participated in another study within the past three months that may interfere with the results or conclusions of this study

• The patient is under judicial protection (prison or custody)

• The patient is an adult under guardianship

• The patient refuses to sign the consent

• History of radical prostatectomy or extensive pelvic surgery

• Evidence of venous leak

• Past radiation therapy of the pelvic region within 12 months prior to enrollment

• Recovering from any cancer within 12 months prior to enrollment

• Neurological disease such as Alzheimer's or Parkinson's disease which affects erectile function at the discretion of the investigator

• Psychiatric diagnosis or medications such as antidepressants, anxiolytic, antipsychotic that affects erectile function or any other medications at the discretion of the investigator

• Anatomical malformation of the penis, including Peyronie's disease

• Testosterone level <300 or >1000 ng/dL within 1 month prior to enrollment

• A1C level > 7% within 1 month prior to enrollment or history of insulin dependent diabetes

• The patient is taking blood thinners and has an international normalized ratio >3

• Received shockwave treatment at least 6 months before enrollment

Related Conditions & MeSH terms

• Erectile Dysfunction

Intervention

Biological:
• VIAGENEX Max
Collagenous membrane derived from umbilical cord

Procedure:
• Hibiclens wash
Antiseptic skin cleanser

Locations

Country	Name	City	State
United States	Atlanta Cosmetic Urology	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
VIVEX Biologics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Penile implant activation	Time to use implant for sexual activity	up to 3 months
Secondary	Pain after undergoing penile prosthesis surgery	Numerical pain scale (0=no pain to 10=worst pain) used to	surgery to 12 months